{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:07:55Z","timestamp":1793938075630,"version":"4.8.0"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1038\/s41571-024-00881-3","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T10:01:59Z","timestamp":1711620119000},"page":"389-400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":620,"title":["Global epidemiology of epithelial ovarian cancer"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0733-5930","authenticated-orcid":false,"given":"Penelope M.","family":"Webb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4566-1414","authenticated-orcid":false,"given":"Susan J.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,28]]},"reference":[{"key":"881_CR1","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/his.14609","volume":"80","author":"WG McCluggage","year":"2022","unstructured":"McCluggage, W. G., Singh, N. & Gilks, C. B. Key changes to the World Health Organization (WHO) classification of female genital tumours introduced in the 5th edition (2020). Histopathology 80, 762\u2013778 (2022).","journal-title":"Histopathology"},{"key":"881_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ajpath.2020.09.006","volume":"191","author":"IM Shih","year":"2021","unstructured":"Shih, I. M., Wang, Y. & Wang, T. L. The origin of ovarian cancer species and precancerous landscape. Am. J. Pathol. 191, 26\u201339 (2021).","journal-title":"Am. J. Pathol."},{"key":"881_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11862-x","volume":"10","author":"D Cheasley","year":"2019","unstructured":"Cheasley, D. et al. The molecular origin and taxonomy of mucinous ovarian carcinoma. Nat. Commun. 10, 3935 (2019).","journal-title":"Nat. Commun."},{"key":"881_CR4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"881_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10552-017-0868-0","volume":"28","author":"PM Webb","year":"2017","unstructured":"Webb, P. M., Green, A. C. & Jordan, S. J. Trends in hormone use and ovarian cancer incidence in US white and Australian women: implications for the future. Cancer Causes Control. 28, 365\u2013370 (2017).","journal-title":"Cancer Causes Control."},{"key":"881_CR6","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/ijc.32322","volume":"146","author":"CJ Cabasag","year":"2020","unstructured":"Cabasag, C. J. et al. The influence of birth cohort and calendar period on global trends in ovarian cancer incidence. Int. J. Cancer 146, 749\u2013758 (2020).","journal-title":"Int. J. Cancer"},{"key":"881_CR7","unstructured":"Ervik, M., Lam, F., Laversanne, M., Ferlay, J. & Bray, F. Global Cancer Observatory: Cancer Over Time https:\/\/gco.iarc.fr\/overtime (2021)."},{"key":"881_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0140-6736(22)01438-6","volume":"400","author":"GBD 2019 Cancer Risk Factors Collaborators.","year":"2022","unstructured":"GBD 2019 Cancer Risk Factors Collaborators. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 400, 563\u2013591 (2022).","journal-title":"Lancet"},{"key":"881_CR9","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1002\/cncr.30528","volume":"123","author":"KC Long Roche","year":"2017","unstructured":"Long Roche, K. C., Abu-Rustum, N. R., Nourmoussavi, M. & Zivanovic, O. Risk-reducing salpingectomy: let us be opportunistic. Cancer 123, 1714\u20131720 (2017).","journal-title":"Cancer"},{"key":"881_CR10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.3390\/cancers15030711","volume":"15","author":"AS Nitschke","year":"2023","unstructured":"Nitschke, A. S., do Valle, H. A., Dawson, L., Kwon, J. S. & Hanley, G. E. Long-term non-cancer risks in people with BRCA mutations following risk-reducing bilateral salpingo-oophorectomy and the role of hormone replacement therapy: a review. Cancers 15, 711 (2023).","journal-title":"Cancers"},{"key":"881_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2015.12.003","volume":"55","author":"SH Yoon","year":"2016","unstructured":"Yoon, S. H., Kim, S. N., Shim, S. H., Kang, S. B. & Lee, S. J. Bilateral salpingectomy can reduce the risk of ovarian cancer in the general population: a meta-analysis. Eur. J. Cancer 55, 38\u201346 (2016).","journal-title":"Eur. J. Cancer"},{"key":"881_CR12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.7150\/jca.21187","volume":"9","author":"Y Chen","year":"2018","unstructured":"Chen, Y., Du, H., Bao, L. & Liu, W. Opportunistic salpingectomy at benign gynecological surgery for reducing ovarian cancer risk: a 10-year single centre experience from China and a literature review. J. Cancer 9, 141\u2013147 (2018).","journal-title":"J. Cancer"},{"key":"881_CR13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.47343","volume":"5","author":"GE Hanley","year":"2022","unstructured":"Hanley, G. E. et al. Outcomes from opportunistic salpingectomy for ovarian cancer prevention. JAMA Netw. Open 5, e2147343 (2022).","journal-title":"JAMA Netw. Open"},{"key":"881_CR14","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1002\/ijc.33714","volume":"149","author":"A Darelius","year":"2021","unstructured":"Darelius, A., Kristjansdottir, B., Dahm-Kahler, P. & Strandell, A. Risk of epithelial ovarian cancer type I and II after hysterectomy, salpingectomy and tubal ligation \u2014 a nationwide case-control study. Int. J. Cancer 149, 1544\u20131552 (2021).","journal-title":"Int. J. Cancer"},{"key":"881_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ygyno.2023.08.016","volume":"177","author":"AH Duus","year":"2023","unstructured":"Duus, A. H., Zheng, G., Baandrup, L., Faber, M. T. & Kjaer, S. K. Risk of ovarian cancer after salpingectomy and tubal ligation: prospects on histology and time since the procedure. Gynecol. Oncol. 177, 125\u2013131 (2023).","journal-title":"Gynecol. Oncol."},{"key":"881_CR16","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.3390\/cancers15041141","volume":"15","author":"E Leblanc","year":"2023","unstructured":"Leblanc, E. et al. Prophylactic radical fimbriectomy with delayed oophorectomy in women with a high risk of developing an ovarian carcinoma: results of a prospective national pilot study. Cancers 15, 1141 (2023).","journal-title":"Cancers"},{"key":"881_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.bpobgyn.2016.08.006","volume":"41","author":"PM Webb","year":"2017","unstructured":"Webb, P. M. & Jordan, S. J. Epidemiology of epithelial ovarian cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 41, 3\u201314 (2017).","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"881_CR18","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1093\/ije\/dyx252","volume":"47","author":"LC Peres","year":"2018","unstructured":"Peres, L. C. et al. Racial\/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int. J. Epidemiol. 47, 460\u2013472 (2018).","journal-title":"Int. J. Epidemiol."},{"key":"881_CR19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1136\/jmedgenet-2013-102015","volume":"51","author":"S Jervis","year":"2014","unstructured":"Jervis, S. et al. Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants. J. Med. Genet. 51, 108\u2013113 (2014).","journal-title":"J. Med. Genet."},{"key":"881_CR20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/cge.13566","volume":"97","author":"N Flaum","year":"2020","unstructured":"Flaum, N., Crosbie, E. J., Edmondson, R. J., Smith, M. J. & Evans, D. G. Epithelial ovarian cancer risk: a review of the current genetic landscape. Clin. Genet. 97, 54\u201363 (2020).","journal-title":"Clin. Genet."},{"key":"881_CR21","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","volume":"2","author":"BM Norquist","year":"2016","unstructured":"Norquist, B. M. et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2, 482\u2013490 (2016).","journal-title":"JAMA Oncol."},{"key":"881_CR22","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/ng.3826","volume":"49","author":"CM Phelan","year":"2017","unstructured":"Phelan, C. M. et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat. Genet. 49, 680\u2013691 (2017).","journal-title":"Nat. Genet."},{"key":"881_CR23","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1200\/JCO.2012.48.2596","volume":"31","author":"VW Setiawan","year":"2013","unstructured":"Setiawan, V. W. et al. Type I and II endometrial cancers: have they different risk factors? J. Clin. Oncol. 31, 2607\u20132618 (2013).","journal-title":"J. Clin. Oncol."},{"key":"881_CR24","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1002\/ijc.27952","volume":"132","author":"TT Gong","year":"2013","unstructured":"Gong, T. T., Wu, Q. J., Vogtmann, E., Lin, B. & Wang, Y. L. Age at menarche and risk of ovarian cancer: a meta-analysis of epidemiological studies. Int. J. Cancer 132, 2894\u20132900 (2013).","journal-title":"Int. J. Cancer"},{"key":"881_CR25","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1200\/JCO.2016.66.8178","volume":"34","author":"N Wentzensen","year":"2016","unstructured":"Wentzensen, N. et al. Ovarian cancer risk factors by histologic subtype: an analysis from the ovarian cancer cohort consortium. J. Clin. Oncol. 34, 2888\u20132898 (2016).","journal-title":"J. Clin. Oncol."},{"key":"881_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002893","volume":"16","author":"J Yarmolinsky","year":"2019","unstructured":"Yarmolinsky, J. et al. Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: a Mendelian randomization analysis. PLoS Med. 16, e1002893 (2019).","journal-title":"PLoS Med."},{"key":"881_CR27","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1002\/cam4.2315","volume":"8","author":"H Yang","year":"2019","unstructured":"Yang, H. et al. Age at menarche and epithelial ovarian cancer risk: a meta-analysis and Mendelian randomization study. Cancer Med. 8, 4012\u20134022 (2019).","journal-title":"Cancer Med."},{"key":"881_CR28","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/jnci\/djad011","volume":"115","author":"Z Fu","year":"2023","unstructured":"Fu, Z. et al. Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis. J. Natl Cancer Inst. 115, 539\u2013551 (2023).","journal-title":"J. Natl Cancer Inst."},{"key":"881_CR29","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/ijc.34192","volume":"151","author":"A Husby","year":"2022","unstructured":"Husby, A., Wohlfahrt, J. & Melbye, M. Pregnancy duration and ovarian cancer risk: a 50-year nationwide cohort study. Int. J. Cancer 151, 1717\u20131725 (2022).","journal-title":"Int. J. Cancer"},{"key":"881_CR30","doi-asserted-by":"publisher","first-page":"BSR20182035","DOI":"10.1042\/BSR20182035","volume":"39","author":"Y Wu","year":"2019","unstructured":"Wu, Y., Sun, W., Xin, X., Wang, W. & Zhang, D. Age at last birth and risk of developing epithelial ovarian cancer: a meta-analysis. Biosci. Rep. 39, BSR20182035 (2019).","journal-title":"Biosci. Rep."},{"key":"881_CR31","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/jnci\/djaa099","volume":"113","author":"AW Lee","year":"2021","unstructured":"Lee, A. W. et al. Expanding our understanding of ovarian cancer risk: the role of incomplete pregnancies. J. Natl Cancer Inst. 113, 301\u2013308 (2021).","journal-title":"J. Natl Cancer Inst."},{"key":"881_CR32","unstructured":"World Cancer Research Fund\/American Institute for Cancer Research. Diet, Nutrition, Physical Activity and Cancer: A Global Perspective (World Cancer Research Fund International, 2018)."},{"key":"881_CR33","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/ijc.31063","volume":"142","author":"K Gaitskell","year":"2018","unstructured":"Gaitskell, K. et al. Histological subtypes of ovarian cancer associated with parity and breastfeeding in the prospective Million Women Study. Int. J. Cancer 142, 281\u2013289 (2018).","journal-title":"Int. J. Cancer"},{"key":"881_CR34","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0421","volume":"6","author":"A Babic","year":"2020","unstructured":"Babic, A. et al. Association between breastfeeding and ovarian cancer risk. JAMA Oncol. 6, e200421 (2020).","journal-title":"JAMA Oncol."},{"key":"881_CR35","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.ygyno.2020.09.037","volume":"159","author":"J Kotsopoulos","year":"2020","unstructured":"Kotsopoulos, J. et al. Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecol. Oncol. 159, 820\u2013826 (2020).","journal-title":"Gynecol. Oncol."},{"key":"881_CR36","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1093\/humrep\/deaa293","volume":"36","author":"JF Barcroft","year":"2021","unstructured":"Barcroft, J. F. et al. Fertility treatment and cancers-the eternal conundrum: a systematic review and meta-analysis. Hum. Reprod. 36, 1093\u20131107 (2021).","journal-title":"Hum. Reprod."},{"key":"881_CR37","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00404-021-06355-6","volume":"306","author":"L Lerner-Geva","year":"2022","unstructured":"Lerner-Geva, L. et al. Subfertility, use of fertility treatments and BRCA mutation status and the risk of ovarian cancer. Arch. Gynecol. Obstet. 306, 209\u2013217 (2022).","journal-title":"Arch. Gynecol. Obstet."},{"key":"881_CR38","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/jnci\/djz015","volume":"111","author":"SC Dixon-Suen","year":"2019","unstructured":"Dixon-Suen, S. C. et al. The association between hysterectomy and ovarian cancer risk: a population-based record-linkage study. J. Natl Cancer Inst. 111, 1097\u20131103 (2019).","journal-title":"J. Natl Cancer Inst."},{"key":"881_CR39","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ygyno.2021.10.088","volume":"164","author":"L Khoja","year":"2022","unstructured":"Khoja, L. et al. Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association. Gynecol. Oncol. 164, 195\u2013201 (2022).","journal-title":"Gynecol. Oncol."},{"key":"881_CR40","doi-asserted-by":"publisher","first-page":"102359","DOI":"10.1016\/j.canep.2023.102359","volume":"84","author":"LL Ring","year":"2023","unstructured":"Ring, L. L. et al. Hysterectomy and risk of epithelial ovarian cancer by histologic type, endometriosis, and menopausal hormone therapy. Cancer Epidemiol. 84, 102359 (2023).","journal-title":"Cancer Epidemiol."},{"key":"881_CR41","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/1471-0528.16943","volume":"129","author":"JA Taylor","year":"2022","unstructured":"Taylor, J. A. et al. Association of hysterectomy and invasive epithelial ovarian and tubal cancer: a cohort study within UKCTOCS. Br. J. Obstet. Gynecol. 129, 110\u2013118 (2022).","journal-title":"Br. J. Obstet. Gynecol."},{"key":"881_CR42","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/ije\/dyt042","volume":"42","author":"W Sieh","year":"2013","unstructured":"Sieh, W. et al. Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. Int. J. Epidemiol. 42, 579\u2013589 (2013).","journal-title":"Int. J. Epidemiol."},{"key":"881_CR43","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","volume":"371","author":"Collaborative Group on Epidemiological Studies of Ovarian Cancer","year":"2008","unstructured":"Collaborative Group on Epidemiological Studies of Ovarian Cancer et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371, 303\u2013314 (2008).","journal-title":"Lancet"},{"key":"881_CR44","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.annepidem.2016.07.004","volume":"26","author":"PG Moorman","year":"2016","unstructured":"Moorman, P. G. et al. Reproductive factors and ovarian cancer risk in African-American women. Ann. Epidemiol. 26, 654\u2013662 (2016).","journal-title":"Ann. Epidemiol."},{"key":"881_CR45","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1158\/1055-9965.EPI-20-0569","volume":"29","author":"D Sarink","year":"2020","unstructured":"Sarink, D. et al. Racial\/ethnic differences in ovarian cancer risk: results from the multiethnic cohort study. Cancer Epidemiol. Biomark. Prev. 29, 2019\u20132025 (2020).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"881_CR46","doi-asserted-by":"publisher","first-page":"51.e1","DOI":"10.1016\/j.ajog.2021.01.014","volume":"225","author":"LH Schrijver","year":"2021","unstructured":"Schrijver, L. H. et al. Oral contraceptive use and ovarian cancer risk for BRCA1\/2 mutation carriers: an international cohort study. Am. J. Obstet. Gynecol. 225, 51.e1\u201351.e17 (2021).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"881_CR47","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ygyno.2022.01.014","volume":"164","author":"YY Xia","year":"2022","unstructured":"Xia, Y. Y. et al. Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecol. Oncol. 164, 514\u2013521 (2022).","journal-title":"Gynecol. Oncol."},{"key":"881_CR48","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/humupd\/dmac038","volume":"29","author":"MHD van Bommel","year":"2023","unstructured":"van Bommel, M. H. D. et al. Contraceptives and cancer risks in BRCA1\/2 pathogenic variant carriers: a systematic review and meta-analysis. Hum. Reprod. Update 29, 197\u2013217 (2023).","journal-title":"Hum. Reprod. Update"},{"key":"881_CR49","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10552-017-0876-0","volume":"28","author":"AL Shafrir","year":"2017","unstructured":"Shafrir, A. L. et al. A prospective cohort study of oral contraceptive use and ovarian cancer among women in the United States born from 1947 to 1964. Cancer Causes Control. 28, 371\u2013383 (2017).","journal-title":"Cancer Causes Control."},{"key":"881_CR50","doi-asserted-by":"publisher","first-page":"k3609","DOI":"10.1136\/bmj.k3609","volume":"362","author":"L Iversen","year":"2018","unstructured":"Iversen, L. et al. Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study. Br. Med. J. 362, k3609 (2018).","journal-title":"Br. Med. J."},{"key":"881_CR51","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(22)00936-9","volume":"400","author":"A Haakenstad","year":"2022","unstructured":"Haakenstad, A. et al. Measuring contraceptive method mix, prevalence, and demand satisfied by age and marital status in 204 countries and territories, 1970-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 400, 295\u2013327 (2022).","journal-title":"Lancet"},{"key":"881_CR52","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1080\/01443615.2020.1789960","volume":"41","author":"J Balayla","year":"2021","unstructured":"Balayla, J., Gil, Y., Lasry, A. & Mitric, C. Ever-use of the intra-uterine device and the risk of ovarian cancer. J. Obstet. Gynaecol. 41, 848\u2013853 (2021).","journal-title":"J. Obstet. Gynaecol."},{"key":"881_CR53","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1158\/1055-9965.EPI-20-1355","volume":"30","author":"MT Phung","year":"2021","unstructured":"Phung, M. T. et al. Depot-medroxyprogesterone acetate use is associated with decreased risk of ovarian cancer: the mounting evidence of a protective role of progestins. Cancer Epidemiol. Biomark. Prev. 30, 927\u2013935 (2021).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"881_CR54","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1007\/s10552-013-0296-8","volume":"24","author":"MT Faber","year":"2013","unstructured":"Faber, M. T. et al. Oral contraceptive use and impact of cumulative intake of estrogen and progestin on risk of ovarian cancer. Cancer Causes Control. 24, 2197\u20132206 (2013).","journal-title":"Cancer Causes Control."},{"key":"881_CR55","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(14)61687-1","volume":"385","author":"Collaborative Group on Epidemiological Studies of Ovarian Cancer","year":"2015","unstructured":"Collaborative Group on Epidemiological Studies of Ovarian Cancer et al. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 385, 1835\u20131842 (2015).","journal-title":"Lancet"},{"key":"881_CR56","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/cncr.23956","volume":"115","author":"CL Pearce","year":"2009","unstructured":"Pearce, C. L., Chung, K., Pike, M. C. & Wu, A. H. Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer 115, 531\u2013539 (2009).","journal-title":"Cancer"},{"key":"881_CR57","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/EDE.0000000000001175","volume":"31","author":"AW Lee","year":"2020","unstructured":"Lee, A. W. et al. Estrogen plus progestin hormone therapy and ovarian cancer: a complicated relationship explored. Epidemiology 31, 402\u2013408 (2020).","journal-title":"Epidemiology"},{"key":"881_CR58","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/jnci\/djad035","volume":"115","author":"A Fournier","year":"2023","unstructured":"Fournier, A. et al. Use of menopausal hormone therapy and ovarian cancer risk in a French cohort study. J. Natl Cancer Inst. 115, 671\u2013679 (2023).","journal-title":"J. Natl Cancer Inst."},{"key":"881_CR59","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.fertnstert.2022.07.019","volume":"118","author":"MT Phung","year":"2022","unstructured":"Phung, M. T. et al. Effects of risk factors for ovarian cancer in women with and without endometriosis. Fertil. Steril. 118, 960\u2013969 (2022).","journal-title":"Fertil. Steril."},{"key":"881_CR60","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s10552-011-9782-z","volume":"22","author":"KK Tsilidis","year":"2011","unstructured":"Tsilidis, K. K. et al. Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition. Cancer Causes Control. 22, 1075\u20131084 (2011).","journal-title":"Cancer Causes Control."},{"key":"881_CR61","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1002\/ijc.31267","volume":"142","author":"ECL Lokkegaard","year":"2018","unstructured":"Lokkegaard, E. C. L. & Morch, L. S. Tibolone and risk of gynecological hormone sensitive cancer. Int. J. Cancer 142, 2435\u20132440 (2018).","journal-title":"Int. J. Cancer"},{"key":"881_CR62","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/GME.0000000000002176","volume":"30","author":"JS Yuk","year":"2023","unstructured":"Yuk, J. S. & Kim, M. Effects of menopausal hormone therapy on the risk of ovarian cancer: health insurance database in South Korea-based cohort study. Menopause 30, 490\u2013496 (2023).","journal-title":"Menopause"},{"key":"881_CR63","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1006\/gyno.2001.6578","volume":"85","author":"P Neven","year":"2002","unstructured":"Neven, P. et al. The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women. Gynecol. Oncol. 85, 388\u2013390 (2002).","journal-title":"Gynecol. Oncol."},{"key":"881_CR64","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1093\/jnci\/djac050","volume":"114","author":"KM Tuesley","year":"2022","unstructured":"Tuesley, K. M. et al. Nitrogen-based bisphosphonate use and ovarian cancer risk in women aged 50 years and older. J. Natl Cancer Inst. 114, 878\u2013884 (2022).","journal-title":"J. Natl Cancer Inst."},{"key":"881_CR65","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/humupd\/dmaa045","volume":"27","author":"M Kvaskoff","year":"2020","unstructured":"Kvaskoff, M. et al. Endometriosis and cancer: a systematic review and meta-analysis. Hum. Reprod. Update 27, 393\u2013420 (2020).","journal-title":"Hum. Reprod. Update"},{"key":"881_CR66","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1097\/AOG.0000000000005191","volume":"141","author":"HR Harris","year":"2023","unstructured":"Harris, H. R. et al. Racial differences in the association of endometriosis and uterine leiomyomas with the risk of ovarian cancer. Obstet. Gynecol. 141, 1124\u20131138 (2023).","journal-title":"Obstet. Gynecol."},{"key":"881_CR67","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1158\/1055-9965.EPI-23-0121","volume":"32","author":"K Gersekowski","year":"2023","unstructured":"Gersekowski, K. et al. Folate intake and ovarian cancer risk among women with endometriosis: a case-control study from the Ovarian Cancer Association Consortium. Cancer Epidemiol. Biomark. Prev. 32, 1087\u20131096 (2023).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"881_CR68","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1158\/1055-9965.EPI-17-0655","volume":"27","author":"HR Harris","year":"2018","unstructured":"Harris, H. R. et al. Polycystic ovary syndrome, oligomenorrhea, and risk of ovarian cancer histotypes: evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiol. Biomark. 27, 174\u2013182 (2018).","journal-title":"Cancer Epidemiol. Biomark."},{"key":"881_CR69","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1093\/ije\/dyz113","volume":"48","author":"HR Harris","year":"2019","unstructured":"Harris, H. R. et al. Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study. Int. J. Epidemiol. 48, 822\u2013830 (2019).","journal-title":"Int. J. Epidemiol."},{"key":"881_CR70","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1002\/ijc.34574","volume":"153","author":"CLB Frandsen","year":"2023","unstructured":"Frandsen, C. L. B. et al. Risk of epithelial ovarian tumors among women with polycystic ovary syndrome: a nationwide population-based cohort study. Int. J. Cancer 153, 958\u2013968 (2023).","journal-title":"Int. J. Cancer"},{"key":"881_CR71","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1001\/jamaoncol.2018.5188","volume":"5","author":"W Yin","year":"2019","unstructured":"Yin, W., Falconer, H., Yin, L., Xu, L. & Ye, W. Association between polycystic ovary syndrome and cancer risk. JAMA Oncol. 5, 106\u2013107 (2019).","journal-title":"JAMA Oncol."},{"key":"881_CR72","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/aje\/kww161","volume":"185","author":"CB Rasmussen","year":"2017","unstructured":"Rasmussen, C. B. et al. Pelvic inflammatory disease and the risk of ovarian cancer and borderline ovarian tumors: a pooled analysis of 13 case-control studies. Am. J. Epidemiol. 185, 8\u201320 (2017).","journal-title":"Am. J. Epidemiol."},{"key":"881_CR73","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.canep.2018.05.011","volume":"55","author":"LM Stewart","year":"2018","unstructured":"Stewart, L. M. et al. Risk of high-grade serous ovarian cancer associated with pelvic inflammatory disease, parity and breast cancer. Cancer Epidemiol. 55, 110\u2013116 (2018).","journal-title":"Cancer Epidemiol."},{"key":"881_CR74","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2020.11.046","volume":"145","author":"H Falconer","year":"2021","unstructured":"Falconer, H., Yin, L., Salehi, S. & Altman, D. Association between pelvic inflammatory disease and subsequent salpingectomy on the risk for ovarian cancer. Eur. J. Cancer 145, 38\u201343 (2021).","journal-title":"Eur. J. Cancer"},{"key":"881_CR75","doi-asserted-by":"publisher","first-page":"75.e1","DOI":"10.1016\/j.ajog.2023.09.094","volume":"230","author":"S Jonsson","year":"2023","unstructured":"Jonsson, S., Jonsson, H., Lundin, E., Haggstrom, C. & Idahl, A. Pelvic inflammatory disease and risk of epithelial ovarian cancer. A national population-based case-control study in Sweden. Am. J. Obstet. Gynecol. 230, 75.e1\u201375.e15 (2023).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"881_CR76","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/jnci\/djy084","volume":"111","author":"B Trabert","year":"2019","unstructured":"Trabert, B. et al. Antibodies against Chlamydia trachomatis and ovarian cancer risk in two independent populations. J. Natl Cancer Inst. 111, 129\u2013136 (2019).","journal-title":"J. Natl Cancer Inst."},{"key":"881_CR77","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/s41416-019-0422-9","volume":"120","author":"RT Fortner","year":"2019","unstructured":"Fortner, R. T. et al. Sexually transmitted infections and risk of epithelial ovarian cancer: results from the Nurses\u2019 Health Studies. Br. J. Cancer 120, 855\u2013860 (2019).","journal-title":"Br. J. Cancer"},{"key":"881_CR78","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1002\/ijc.32999","volume":"147","author":"A Idahl","year":"2020","unstructured":"Idahl, A. et al. Serologic markers of Chlamydia trachomatis and other sexually transmitted infections and subsequent ovarian cancer risk: results from the EPIC cohort. Int. J. Cancer 147, 2042\u20132052 (2020).","journal-title":"Int. J. Cancer"},{"key":"881_CR79","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-040137","volume":"10","author":"LH Wang","year":"2020","unstructured":"Wang, L. H., Zhong, L., Xu, B., Chen, M. & Huang, H. X. Diabetes mellitus and the risk of ovarian cancer: a systematic review and meta-analysis of cohort and case-control studies. BMJ Open 10, e040137 (2020).","journal-title":"BMJ Open"},{"key":"881_CR80","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10654-018-0438-0","volume":"34","author":"K Saarela","year":"2019","unstructured":"Saarela, K., Tuomilehto, J., Sund, R., Keskim\u00e4ki, I. & Hartikainen, S. Cancer incidence among Finnish people with type 2 diabetes during 1989\u20132014. Eur. J. Epidemiol. 34, 259\u2013265 (2019).","journal-title":"Eur. J. Epidemiol."},{"key":"881_CR81","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.2337\/db20-0084","volume":"69","author":"S Yuan","year":"2020","unstructured":"Yuan, S. et al. Is type 2 diabetes causally associated with cancer risk? evidence from a two-sample mendelian randomization study. Diabetes 69, 1588\u20131596 (2020).","journal-title":"Diabetes"},{"key":"881_CR82","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1158\/1055-9965.EPI-20-1245","volume":"30","author":"J Pearson-Stuttard","year":"2021","unstructured":"Pearson-Stuttard, J. et al. Type 2 diabetes and cancer: an umbrella review of observational and mendelian randomization studies. Cancer Epidemiol. Biomark. Prev. 30, 1218\u20131228 (2021).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"881_CR83","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.21037\/atm-20-1060","volume":"8","author":"E Urpilainen","year":"2020","unstructured":"Urpilainen, E., Puistola, U., Boussios, S. & Karihtala, P. Metformin and ovarian cancer: the evidence. Ann. Transl. Med. 8, 1711 (2020).","journal-title":"Ann. Transl. Med."},{"key":"881_CR84","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.0666","volume":"6","author":"LM Hurwitz","year":"2023","unstructured":"Hurwitz, L. M. et al. Association of frequent aspirin use with ovarian cancer risk according to genetic susceptibility. JAMA Netw. Open 6, e230666 (2023).","journal-title":"JAMA Netw. Open"},{"key":"881_CR85","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/annonc\/mdu578","volume":"26","author":"L Baandrup","year":"2015","unstructured":"Baandrup, L., Kjaer, S. K., Olsen, J. H., Dehlendorff, C. & Friis, S. Low-dose aspirin use and the risk of ovarian cancer in Denmark. Ann. Oncol. 26, 787\u2013792 (2015).","journal-title":"Ann. Oncol."},{"key":"881_CR86","doi-asserted-by":"publisher","first-page":"4207","DOI":"10.1200\/JCO.21.01900","volume":"40","author":"LM Hurwitz","year":"2022","unstructured":"Hurwitz, L. M. et al. Modification of the association between frequent aspirin use and ovarian cancer risk: a meta-analysis using individual-level data from two ovarian cancer consortia. J. Clin. Oncol. 40, 4207\u20134217 (2022).","journal-title":"J. Clin. Oncol."},{"key":"881_CR87","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/jnci\/djy100","volume":"111","author":"B Trabert","year":"2019","unstructured":"Trabert, B. et al. Analgesic use and ovarian cancer risk: an analysis in the ovarian cancer cohort consortium. J. Natl Cancer Inst. 111, 137\u2013145 (2019).","journal-title":"J. Natl Cancer Inst."},{"key":"881_CR88","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1158\/1940-6207.CAPR-22-0374","volume":"16","author":"OA Zeleznik","year":"2023","unstructured":"Zeleznik, O. A., Irvin, S. R., Samimi, G. & Trabert, B. The role of statins in the prevention of ovarian and endometrial cancers. Cancer Prev. Res. 16, 191\u2013197 (2023).","journal-title":"Cancer Prev. Res."},{"key":"881_CR89","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1001\/jama.2020.0150","volume":"323","author":"J Yarmolinsky","year":"2020","unstructured":"Yarmolinsky, J. et al. Association between genetically proxied inhibition of HMG-CoA reductase and epithelial ovarian cancer. J. Am. Med. Assoc. 323, 646\u2013655 (2020).","journal-title":"J. Am. Med. Assoc."},{"key":"881_CR90","doi-asserted-by":"publisher","first-page":"102444","DOI":"10.1016\/j.canep.2023.102444","volume":"86","author":"KM Tuesley","year":"2023","unstructured":"Tuesley, K. M. et al. Association between antihypertensive medicine use and risk of ovarian cancer in women aged 50 years and older. Cancer Epidemiol. 86, 102444 (2023).","journal-title":"Cancer Epidemiol."},{"key":"881_CR91","doi-asserted-by":"publisher","first-page":"939636","DOI":"10.3389\/fonc.2022.939636","volume":"12","author":"YJ Zhuang","year":"2022","unstructured":"Zhuang, Y. J. et al. The incidence risk of breast and gynecological cancer by antidepressant use: a systematic review and dose-response meta-analysis of epidemiological studies involving 160,727 patients. Front. Oncol. 12, 939636 (2022).","journal-title":"Front. Oncol."},{"key":"881_CR92","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1056\/NEJMsr1606602","volume":"375","author":"B Lauby-Secretan","year":"2016","unstructured":"Lauby-Secretan, B. et al. Body fatness and cancer \u2014 viewpoint of the IARC Working Group. N. Engl. J. Med. 375, 794\u2013798 (2016).","journal-title":"N. Engl. J. Med."},{"key":"881_CR93","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1093\/ije\/dyw158","volume":"45","author":"SC Dixon","year":"2016","unstructured":"Dixon, S. C. et al. Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. Int. J. Epidemiol. 45, 884\u2013895 (2016).","journal-title":"Int. J. Epidemiol."},{"key":"881_CR94","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/1878-0261.12772","volume":"15","author":"CM Friedenreich","year":"2021","unstructured":"Friedenreich, C. M., Ryder-Burbidge, C. & McNeil, J. Physical activity, obesity and sedentary behavior in cancer etiology: epidemiologic evidence and biologic mechanisms. Mol. Oncol. 15, 790\u2013800 (2021).","journal-title":"Mol. Oncol."},{"key":"881_CR95","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003706","volume":"18","author":"M Vithayathil","year":"2021","unstructured":"Vithayathil, M. et al. Body size and composition and risk of site-specific cancers in the UK Biobank and large international consortia: a Mendelian randomisation study. PLoS Med. 18, e1003706 (2021).","journal-title":"PLoS Med."},{"key":"881_CR96","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1530\/ERC-12-0395","volume":"20","author":"CM Olsen","year":"2013","unstructured":"Olsen, C. M. et al. Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocr. Relat. Cancer 20, 251\u2013262 (2013).","journal-title":"Endocr. Relat. Cancer"},{"key":"881_CR97","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1158\/1055-9965.EPI-18-0024","volume":"28","author":"J Aarestrup","year":"2019","unstructured":"Aarestrup, J. et al. Childhood overweight, tallness, and growth increase risks of ovarian cancer. Cancer Epidemiol. Biomark. Prev. 28, 183\u2013188 (2019).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"881_CR98","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/SLA.0000000000002525","volume":"269","author":"DP Schauer","year":"2019","unstructured":"Schauer, D. P. et al. Bariatric surgery and the risk of cancer in a large multisite cohort. Ann. Surg. 269, 95\u2013101 (2019).","journal-title":"Ann. Surg."},{"key":"881_CR99","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1158\/1055-9965.EPI-15-1330","volume":"25","author":"R Cannioto","year":"2016","unstructured":"Cannioto, R. et al. Chronic recreational physical inactivity and epithelial ovarian cancer risk: evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiol. Biomark. Prev. 25, 1114\u20131124 (2016).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"881_CR100","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1249\/MSS.0000000000001937","volume":"51","author":"A McTiernan","year":"2019","unstructured":"McTiernan, A. et al. Physical activity in cancer prevention and survival: a systematic review. Med. Sci. Sports Exerc. 51, 1252\u20131261 (2019).","journal-title":"Med. Sci. Sports Exerc."},{"key":"881_CR101","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s10654-020-00712-6","volume":"36","author":"VS Biller","year":"2021","unstructured":"Biller, V. S. et al. Sedentary behaviour in relation to ovarian cancer risk: a systematic review and meta-analysis. Eur. J. Epidemiol. 36, 769\u2013780 (2021).","journal-title":"Eur. J. Epidemiol."},{"key":"881_CR102","doi-asserted-by":"publisher","first-page":"13623","DOI":"10.1002\/cam4.5974","volume":"12","author":"JW Chen","year":"2023","unstructured":"Chen, J. W. et al. Genetic associations of leisure sedentary behaviors and the risk of 15 site-specific cancers: a Mendelian randomization study. Cancer Med. 12, 13623\u201313636 (2023).","journal-title":"Cancer Med."},{"key":"881_CR103","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001200","volume":"9","author":"Collaborative Group on Epidemiological Studies of Ovarian Cancer.","year":"2012","unstructured":"Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and body size: individual participant meta-analysis including 25157 women with ovarian cancer from 47 epidemiological studies. PLoS Med. 9, e1001200 (2012).","journal-title":"PLoS Med."},{"key":"881_CR104","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s10552-013-0174-4","volume":"24","author":"MT Faber","year":"2013","unstructured":"Faber, M. T. et al. Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. Cancer Causes Control. 24, 989\u20131004 (2013).","journal-title":"Cancer Causes Control."},{"key":"881_CR105","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1158\/1055-9965.EPI-20-1803","volume":"30","author":"JA Baron","year":"2021","unstructured":"Baron, J. A., Nichols, H. B., Anderson, C. & Safe, S. Cigarette smoking and estrogen-related cancer. Cancer Epidemiol. Biomark. Prev. 30, 1462\u20131471 (2021).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"881_CR106","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1002\/ijc.31257","volume":"142","author":"KP Ko","year":"2018","unstructured":"Ko, K. P. et al. The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers. Int. J. Cancer 142, 2263\u20132272 (2018).","journal-title":"Int. J. Cancer"},{"key":"881_CR107","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-23-0984","author":"K Gersekowski","year":"2024","unstructured":"Gersekowski, K. et al. Risk factors for ovarian cancer by BRCA status: a collaborative case-only analysis. Cancer Epidemiol. Biomark. Prev. https:\/\/doi.org\/10.1158\/1055-9965.EPI-23-0984 (2024).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"881_CR108","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/bjc.2011.254","volume":"105","author":"Endogenous Hormones Breast Cancer Collaborative Group","year":"2011","unstructured":"Endogenous Hormones Breast Cancer Collaborative Group et al. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br. J. Cancer 105, 709\u2013722 (2011).","journal-title":"Br. J. Cancer"},{"key":"881_CR109","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003178","volume":"17","author":"SC Larsson","year":"2020","unstructured":"Larsson, S. C. et al. Smoking, alcohol consumption, and cancer: a mendelian randomisation study in UK Biobank and international genetic consortia participants. PLoS Med. 17, e1003178 (2020).","journal-title":"PLoS Med."},{"key":"881_CR110","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1093\/ije\/dyz144","volume":"48","author":"JS Ong","year":"2019","unstructured":"Ong, J. S. et al. Association between coffee consumption and overall risk of being diagnosed with or dying from cancer among >300 000 UK Biobank participants in a large-scale Mendelian randomization study. Int. J. Epidemiol. 48, 1447\u20131456 (2019).","journal-title":"Int. J. Epidemiol."},{"key":"881_CR111","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nrc2641","volume":"9","author":"CS Yang","year":"2009","unstructured":"Yang, C. S., Wang, X., Lu, G. & Picinich, S. C. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat. Rev. Cancer 9, 429\u2013439 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"881_CR112","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/jn\/nxz165","volume":"149","author":"DA Byrd","year":"2019","unstructured":"Byrd, D. A. et al. Development and validation of novel dietary and lifestyle inflammation scores. J. Nutr. 149, 2206\u20132218 (2019).","journal-title":"J. Nutr."},{"key":"881_CR113","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1080\/01635581.2021.1931366","volume":"74","author":"J Yang","year":"2022","unstructured":"Yang, J. et al. Dietary inflammatory index and ovarian cancer risk: a meta-analysis. Nutr. Cancer 74, 796\u2013805 (2022).","journal-title":"Nutr. Cancer"},{"key":"881_CR114","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/ijc.32105","volume":"145","author":"FJ Vojdeman","year":"2019","unstructured":"Vojdeman, F. J. et al. Vitamin D levels and cancer incidence in 217,244 individuals from primary health care in Denmark. Int. J. Cancer 145, 338\u2013346 (2019).","journal-title":"Int. J. Cancer"},{"key":"881_CR115","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1093\/annonc\/mdz059","volume":"30","author":"N Keum","year":"2019","unstructured":"Keum, N., Lee, D. H., Greenwood, D. C., Manson, J. E. & Giovannucci, E. Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials. Ann. Oncol. 30, 733\u2013743 (2019).","journal-title":"Ann. Oncol."},{"key":"881_CR116","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20368-w","volume":"12","author":"JS Ong","year":"2021","unstructured":"Ong, J. S. et al. A comprehensive re-assessment of the association between vitamin D and cancer susceptibility using Mendelian randomization. Nat. Commun. 12, 246 (2021).","journal-title":"Nat. Commun."},{"key":"881_CR117","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ygyno.2021.07.032","volume":"163","author":"N Wentzensen","year":"2021","unstructured":"Wentzensen, N. & O\u2019Brien, K. M. Talc, body powder, and ovarian cancer: a summary of the epidemiologic evidence. Gynecol. Oncol. 163, 199\u2013208 (2021).","journal-title":"Gynecol. Oncol."},{"key":"881_CR118","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1001\/jama.2019.20079","volume":"323","author":"KM O\u2019Brien","year":"2020","unstructured":"O\u2019Brien, K. M. et al. Association of powder use in the genital area with risk of ovarian cancer. J. Am. Med. Assoc. 323, 49\u201359 (2020).","journal-title":"J. Am. Med. Assoc."},{"key":"881_CR119","first-page":"60","volume":"195","author":"M Utada","year":"2021","unstructured":"Utada, M. et al. Radiation risk of ovarian cancer in atomic bomb survivors: 1958-2009. Radiat. Res. 195, 60\u201365 (2021).","journal-title":"Radiat. Res."},{"key":"881_CR120","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1158\/1055-9965.EPI-18-1112","volume":"28","author":"L Leung","year":"2019","unstructured":"Leung, L. et al. Shift work patterns, chronotype, and epithelial ovarian cancer risk. Cancer Epidemiol. Biomark. Prev. 28, 987\u2013995 (2019).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"881_CR121","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1158\/1940-6207.CAPR-20-0174","volume":"14","author":"X Liang","year":"2021","unstructured":"Liang, X. et al. Sleep characteristics and risk of ovarian cancer among postmenopausal women. Cancer Prev. Res. 14, 55\u201364 (2021).","journal-title":"Cancer Prev. Res."},{"key":"881_CR122","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.bpobgyn.2020.02.010","volume":"65","author":"Z Nash","year":"2020","unstructured":"Nash, Z. & Menon, U. Ovarian cancer screening: current status and future directions. Best Pract. Res. Clin. Obstet. Gynaecol. 65, 32\u201345 (2020).","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"881_CR123","doi-asserted-by":"publisher","first-page":"397.e391","DOI":"10.1016\/j.ajog.2021.03.032","volume":"225","author":"RW Naumann","year":"2021","unstructured":"Naumann, R. W., Hughes, B. N., Brown, J., Drury, L. K. & Herzog, T. J. The impact of opportunistic salpingectomy on ovarian cancer mortality and healthcare costs: a call for universal insurance coverage. Am. J. Obstet. Gynecol. 225, 397.e391\u2013397.e6 (2021).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"881_CR124","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-018-3083-8","volume":"20","author":"A Idahl","year":"2019","unstructured":"Idahl, A., Darelius, A., Sundfeldt, K., Palsson, M. & Strandell, A. Hysterectomy and opportunistic salpingectomy (HOPPSA): study protocol for a register-based randomized controlled trial. Trials 20, 10 (2019).","journal-title":"Trials"},{"key":"881_CR125","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1136\/ijgc-2023-004377","volume":"33","author":"MP Steenbeek","year":"2023","unstructured":"Steenbeek, M. P. et al. TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol. Int. J. Gynecol. Cancer 33, 982\u2013987 (2023).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"881_CR126","doi-asserted-by":"publisher","unstructured":"Huh, W. et al. NRG-CC008: a nonrandomized prospective clinical trial comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers [SOROCk]. J. Clin. Oncol. 60, https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS106 (2022).","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS106"},{"key":"881_CR127","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.bpobgyn.2020.02.007","volume":"65","author":"O Evans","year":"2020","unstructured":"Evans, O., Gaba, F. & Manchanda, R. Population-based genetic testing for women\u2019s cancer prevention. Best Pract. Res. Clin. Obstet. Gynaecol. 65, 139\u2013153 (2020).","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"881_CR128","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","volume":"30","author":"K Alsop","year":"2012","unstructured":"Alsop, K. et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J. Clin. Oncol. 30, 2654\u20132663 (2012).","journal-title":"J. Clin. Oncol."},{"key":"881_CR129","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1200\/JCO.19.02960","volume":"38","author":"PA Konstantinopoulos","year":"2020","unstructured":"Konstantinopoulos, P. A. et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. J. Clin. Oncol. 38, 1222\u20131245 (2020).","journal-title":"J. Clin. Oncol."},{"key":"881_CR130","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1200\/JCO.2016.70.3439","volume":"35","author":"G Samimi","year":"2017","unstructured":"Samimi, G. et al. Traceback: a proposed framework to increase identification and genetic counseling of BRCA1 and BRCA2 mutation carriers through family-based outreach. J. Clin. Oncol. 35, 2329\u20132337 (2017).","journal-title":"J. Clin. Oncol."},{"key":"881_CR131","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/s41416-018-0029-6","volume":"118","author":"KF Brown","year":"2018","unstructured":"Brown, K. F. et al. The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015. Br. J. Cancer 118, 1130\u20131141 (2018).","journal-title":"Br. J. Cancer"},{"key":"881_CR132","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/1753-6405.12457","volume":"39","author":"SJ Jordan","year":"2015","unstructured":"Jordan, S. J. et al. Cancers in Australia in 2010 attributable to total breastfeeding durations of 12 months or less by parous women. Aust. N. Z. J. Public Health 39, 418\u2013421 (2015).","journal-title":"Aust. N. Z. J. Public Health"},{"key":"881_CR133","unstructured":"ClinicalTrials.gov. US National Library of Medicine https:\/\/clinicaltrials.gov\/study\/NCT03480776 (2023)."},{"key":"881_CR134","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1001\/jama.2021.0278","volume":"325","author":"D Appiah","year":"2021","unstructured":"Appiah, D., Nwabuo, C. C., Ebong, I. A., Wellons, M. F. & Winters, S. J. Trends in age at natural menopause and reproductive life span among US women, 1959-2018. J. Am. Med. Assoc. 325, 1328\u20131330 (2021).","journal-title":"J. Am. Med. Assoc."},{"key":"881_CR135","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-13656-1","volume":"22","author":"H Cheng","year":"2022","unstructured":"Cheng, H. et al. Global trends in total fertility rate and its relation to national wealth, life expectancy and female education. BMC Public Health 22, 1346 (2022).","journal-title":"BMC Public Health"},{"key":"881_CR136","doi-asserted-by":"publisher","first-page":"155217","DOI":"10.1016\/j.metabol.2022.155217","volume":"133","author":"C Boutari","year":"2022","unstructured":"Boutari, C. & Mantzoros, C. S. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism 133, 155217 (2022).","journal-title":"Metabolism"},{"key":"881_CR137","unstructured":"Kurman, R., Carcangiu, M., Herrington, C. & Young, R. WHO Classification of Tumours. Female Reproductive Organs (IARC, 2014)."},{"key":"881_CR138","unstructured":"Surveillance Epidemiology and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence \u2014 SEER Research Plus Data with Delay-Adjustment, 17 Registries, Malignant Only, Nov 2022 Sub (2000-2020) \u2014 Linked To County Attributes \u2014 Total U.S., 1969-2021 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2023, based on the November 2022 submission (accessed 2023)."},{"key":"881_CR139","unstructured":"Australian Institute of Health and Welfare (AIHW). Cancer Data in Australia https:\/\/www.aihw.gov.au\/reports\/cancer\/cancer-data-in-australia\/ (2023)."},{"key":"881_CR140","unstructured":"Lar\u00f8nningen, S. et al. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 9.3 (02.10.2023). Association of the Nordic Cancer Registries. Cancer Registry of Norway. Available from: https:\/\/nordcan.iarc.fr\/, (accessed 22 October 2023)."},{"key":"881_CR141","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1158\/1055-9965.EPI-14-0300","volume":"23","author":"PS Rosenberg","year":"2014","unstructured":"Rosenberg, P. S., Check, D. P. & Anderson, W. F. A web tool for age-period-cohort analysis of cancer incidence and mortality rates. Cancer Epidemiol. Biomark. Prev. 23, 2296\u20132302 (2014).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"881_CR142","unstructured":"The US National Cancer Institute. Site Recode ICD-O-3 2023 Revision Expanded Definition https:\/\/seer.cancer.gov\/siterecode\/icdo3_2023_expanded\/ (2024)."},{"key":"881_CR143","unstructured":"WHO Classification of Tumours Editorial Board. World Health Organization Classification of Female Genital Tumours. 5th Edition (IARC Press, 2020)."},{"key":"881_CR144","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/PGP.0000000000000336","volume":"36","author":"WG McCluggage","year":"2017","unstructured":"McCluggage, W. G., Hirschowitz, L., Gilks, C. B., Wilkinson, N. & Singh, N. The fallopian tube origin and primary site assignment in extrauterine high-grade serous carcinoma: findings of a survey of pathologists and clinicians. Int. J. Gynecol. Pathol. 36, 230\u2013239 (2017).","journal-title":"Int. J. Gynecol. Pathol."},{"key":"881_CR145","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/ijgo.13871","volume":"155","author":"WG McCluggage","year":"2021","unstructured":"McCluggage, W. G. Progress in the pathological arena of gynecological cancers. Int. J. Gynaecol. Obstet. 155, 107\u2013114 (2021).","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"881_CR146","unstructured":"Cancer Research UK. Ovarian Cancer Incidence Statistics https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/ovarian-cancer\/incidence#collapseTwo (2024)."},{"key":"881_CR147","unstructured":"National Cancer Institute (NCI). Cancer Stat Facts: Ovarian Cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html (accessed 31 January 2024)."},{"key":"881_CR148","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/jamaoncol.2021.6987","volume":"8","author":"Global Burden of Disease Cancer Collaboration, et al.","year":"2022","unstructured":"Global Burden of Disease Cancer Collaboration et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 8, 420\u2013444 (2022).","journal-title":"JAMA Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00881-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00881-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00881-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T09:12:03Z","timestamp":1713949923000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00881-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,28]]},"references-count":148,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["881"],"URL":"https:\/\/doi.org\/10.1038\/s41571-024-00881-3","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,28]]},"assertion":[{"value":"4 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.M.W. has received speaker\u2019s fees and research funding from AstraZeneca. S.J.J. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}